FDA ADCOMM VOTE: Should a regulatory decision on retifanlimab for the treatment of advanced or metastatic squamous carcinoma of the anal canal be deferred until further data are available from clinical trial POD1UM303? 13-Yes 4-No 0-Abstain$INCY
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.